Drug Database · Clinicians

Amlodipine + Telmisartan

Brands (120) Telmez CCB, Team Duo, Valugan…Show all
Telmez CCB · Team Duo · Valugan · Amcardis · Amlotel · Angical · Cilzec-A · Mistacor AM · Mistasyl · Natras Duo · Telarb CCB · Telmal · Telmiget Duo · Telmilop · Telmipin · Telmirx Plus · Telzarpin · Temsta · Twynsta · Vasatraz · Zenovia · Actarb-A · Misarven A · Telmiprem Plus · Cardialta · Duostar · Lynsta · SarTam · Synergia · Tarsina Plus · TeliSolv Pro · Telmicass Plus · Telmilife · Telmimore · Telpine-AM · Telstar Duo® · Tepriva · Vasoduo · Zardip Duo · Amity 40/10 · Amity 40/5 · Amity 80/10 · Amity 80/5 · Amplify 40/10 · Amplify 40/5 · Amplify 80/10 · Amplify 80/5 · Amtera Bp · Angiotor · Angiotor 80/10 · Arb Duo · Besylon Plus · Beztel · Blitensta · Blitensta X · Co-Midis · Corvita 40/10 · Corvita 40/5 · Corvita 80/10 · Corvita 80/5 · Corzap Max · Corzap Plus · Medivasc · Misarpin · Mistralix · Protelmisarpine · Retatel Plus 40/10 · Retatel Plus 40/5 · Retatel Plus 80/10 · Retatel Plus 80/5 · Saphtelo-G45 · Saphtelo-G50 · Saphtelo-G85 · Saphtelo-G90 · Syntam 40/10 · Syntam 40/5 · Syntam 80/10 · Syntam 80/5 · TAMILOPIN-40 · Tamilopin-80 · TEL-AMLO 40 · Tel-Amlo 80 · Telam · Telamed · Telday Amlo 40/5 · Telday Amlo 80/10 · Telday Amlo 80/5 · Telfort AM 40/5 · Telfort AM 80/10 · Telgrand-Am · TeliDril 40 Pro · TeliDril 80 Pro · TeliGen-40 Pro · TeliGen-80 Pro. · Telmefixx Plus · Telmifer+ · Telmikem-Am · Telmisaph-A45 · Telmisaph-A50 · Telmisaph-A85 · Telmisaph-A90 · Telmisar AM · Telmisar AM- 80 · Telmistal AM 45 · Telmistal AM 85 · Telmistal AM 90 · Telmix 45 · TELMLOSPAR-85 · Telovasc · Telvasc · Tevex-A40/5 · Tevex-A80/10 · Tevex-A80/5 · Tezart 80/10 · Vasotrel 80 Plus · Zamplify 40/10 · Zamplify 40/5 · Zamplify 80/10 · Zamplify 80/5 · Zermisar Plus 40/5

US brand (reference label): Telmisartan and Amlodipine; not a Philippine-registered brand.

Angiotensin 2 Receptor Blocker (Angiotensin 2 Receptor Antagonists) US FDA class
Angiotensin II receptor blocker - calcium channel blocker combination; Angiotensin ii receptor blocker - calcium channel blocker combinatiion; and others PH FDA category
Fixed-dose combination.

Rx · Prescription drug247 PH productsVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 15b438b4-4874-43f4-a50a-4e6f3e5530ac, version date October 26, 2026 (Telmisartan and Amlodipine · Alembic Pharmaceuticals Limited). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Telmisartan and amlodipine tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure.
  • · Telmisartan and amlodipine tablets are indicated as initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Telmisartan and amlodipine tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin II receptor blockers and dihydropyridine calcium channel blockers.

There are no controlled trials demonstrating risk reduction with telmisartan and amlodipine tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.

Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Telmisartan and amlodipine tablets may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.

Base the choice of telmisartan and amlodipine tablets as initial therapy for hypertension on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of telmisartan and amlodipine tablets. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant.

Consider the patient’s baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy when deciding whether to use telmisartan and amlodipine tablets as initial therapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, multidose, factorial trial provide estimates of the probability of reaching a blood pressure goal with telmisartan and amlodipine tablets compared to telmisartan or amlodipine monotherapy and placebo [see Clinical Studies (14.1)].

The figures below provide estimates of the likelihood of achieving systolic and diastolic blood pressure control with telmisartan and amlodipine 80/10 mg tablets, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures.

The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal at 8 weeks. For example, a patient with a baseline blood pressure of 160/110 mmHg has about a 16% likelihood of achieving a goal of <140 mmHg (systolic) and 16% likelihood of achieving <90 mmHg (diastolic) on placebo.

The likelihood of achieving these same goals on telmisartan is about 46% (systolic) and 26% (diastolic). The likelihood of achieving these same goals on amlodipine is about 69% (systolic) and 22% (diastolic). These likelihoods rise to 79% for systolic and 55% for diastolic with telmisartan and amlodipine tablets. · Telmisartan and amlodipine tablet is an angiotensin II receptor blocker (ARB) and a dihydropyridine calcium channel blocker (DHP-CCB) combination product indicated for the treatment of hypertension alone or with other antihypertensive agents to lower blood pressure.

Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1) · Telmisartan and amlodipine tablets are indicated as initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals (1) Figure

Contraindications

4 CONTRAINDICATIONS Telmisartan and amlodipine tablets are contraindicated in patients with known hypersensitivity (e.g., anaphylaxis or angioedema) to telmisartan, amlodipine, or any other component of this product [see Adverse Reactions (6.2)]. Do not co-administer aliskiren with telmisartan and amlodipine tablets in patients with diabetes [see Drug Interactions (7.2)].

Known hypersensitivity (e.g., anaphylaxis or angioedema) to telmisartan, amlodipine or any other component of this product (4) Do not co-administer aliskiren with telmisartan and amlodipine tablets in patients with diabetes (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • Substitute telmisartan and amlodipine tablets for its individually titrated components for patients on amlodipine and telmisartan. Telmisartan and amlodipine tablets may also be given with increased amounts of amlodipine, telmisartan, or both, as needed. (2.2, 2.3)
  • Use telmisartan and amlodipine tablets to provide additional blood pressure lowering for patients not adequately controlled with amlodipine (or another dihydropyridine calcium channel blocker) alone or with telmisartan (or another angiotensin receptor blocker) alone (2.3)
  • Dosage may be increased after at least 2 weeks to a maximum dose of 80/10 mg once daily, usually by increasing one component at a time but both components can be raised to achieve more rapid control (2.1, 2.2)
  • Majority of antihypertensive effect is attained within 2 weeks (2.1)
  • Initiate with 40/5 mg or 80/5 mg once daily (2.4)
  • Switch patients who experience dose-limiting adverse reactions on amlodipine to telmisartan and amlodipine tablets containing a lower dose of that component (2.3)
2.1 General Considerations

2.1 General Considerations Telmisartan is an effective treatment of hypertension in once daily doses of 20 to 80 mg while amlodipine is effective in doses of 2.5 to 10 mg. Dosage must be individualized and may be increased after at least 2 weeks. Most of the antihypertensive effect is apparent within 2 weeks and maximal reduction is generally attained after 4 weeks.

The maximum recommended dose of telmisartan and amlodipine tablet is 80/10 mg once daily. The adverse reactions of telmisartan are uncommon and independent of dose; those of amlodipine are a mixture of dose-dependent phenomena (primarily peripheral edema) and dose-independent phenomena, the former much more common than the latter [see Adverse Reactions (6.1)].

Telmisartan and amlodipine tablets may be taken with or without food.

2.2 Replacement Therapy

2.2 Replacement Therapy Patients receiving amlodipine and telmisartan from separate tablets may instead receive telmisartan and amlodipine tablets containing the same component doses once daily. When substituting for individual components, increase the dose of telmisartan and amlodipine tablets if blood pressure control has not been satisfactory.

2.3 Add-on Therapy for Patients with Hypertension Not Adequately Controlled on…

2.3 Add-on Therapy for Patients with Hypertension Not Adequately Controlled on Antihypertensive Monotherapy Telmisartan and amlodipine tablets may be used to provide additional blood pressure lowering for patients not adequately controlled with amlodipine (or another dihydropyridine calcium channel blocker) alone or with telmisartan (or another angiotensin receptor blocker) alone. Patients treated with 10 mg amlodipine who experience any dose-limiting adverse reactions such as edema, may be switched to telmisartan and amlodipine 40/5 mg tablets once daily, reducing the dose of amlodipine without reducing the overall expected antihypertensive response [see Adverse Reactions (6.1)].

2.4 Initial Therapy

2.4 Initial Therapy A patient may be initiated on telmisartan and amlodipine tablets if it is unlikely that control of blood pressure would be achieved with a single agent. The usual starting dose of telmisartan and amlodipine tablet is 40/5 mg once daily. Patients requiring larger blood pressure reductions may be started on telmisartan and amlodipine tablet 80/5 mg once daily.

Initial therapy with telmisartan and amlodipine tablet is not recommended in patients ≥75 years old or with hepatic impairment [see Dosage and Administration (2.5), Warnings and Precautions (5.4), and Use in Specific Populations (8.5, 8.6)]. Correct imbalances of intravascular volume- or salt-depletion, before initiating therapy with telmisartan and amlodipine tablets [see Warnings and Precautions (5.2)].

2.5 Dosing in Specific Populations Renal Impairment

2.5 Dosing in Specific Populations Renal Impairment No initial dosage adjustment is required for patients with mild or moderate renal impairment. Titrate slowly in patients with severe renal impairment. Hepatic Impairment In most patients, initiate amlodipine therapy at 2.5 mg. Titrate slowly in patients with hepatic impairment.

Patients 75 Years of Age and Older In most patients, initiate amlodipine therapy at 2.5 mg. Titrate slowly in patients 75 years of age and older.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (dosage and administration, pharmacokinetics)

2.5 Dosing in Specific Populations Renal Impairment No initial dosage adjustment is required for patients with mild or moderate renal impairment. Titrate slowly in patients with severe renal impairment. Hepatic Impairment In most patients, initiate amlodipine therapy at 2.5 mg. Titrate slowly in patients with hepatic impairment. Patients 75 Years of Age and Older In most patients, initiate amlodipine therapy at 2.5 mg. Titrate slowly in patients 75 years of age and older.

Renal Insufficiency Telmisartan: No dosage adjustment is necessary in patients with decreased renal function. Telmisartan is not removed from blood by hemofiltration [see Warnings and Precautions (5.5)]. Amlodipine: The pharmacokinetics of amlodipine are not significantly influenced by renal impairment.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.6 Hepatic Insufficiency Monitor carefully and uptitrate slowly in patients with biliary obstructive disorders or hepatic insufficiency [see Dosage and Administration (2) and Warnings and Precautions (5.4)]. Since patients with hepatic impairment have decreased clearance of amlodipine, start amlodipine or add amlodipine 2.5 mg to telmisartan. The lowest dose of telmisartan and amlodipine tablet is 40/5 mg; therefore, initial therapy with telmisartan and amlodipine tablet is not recommended in hepatically impaired patients [see Dosage and Administration (2.4)].

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Safety and effectiveness of telmisartan and amlodipine tablets in pediatric patients have not been established. Neonates with a history of in utero exposure to telmisartan and amlodipine tablets: If oliguria or hypotension occurs, support blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Telmisartan and amlodipine tablets Of the total number of 3282 hypertensive patients receiving a telmisartan/amlodipine combination in clinical studies, 605 (18%) patients were 65 years of age or older and of these, 88 (3%) patients were 75 years and older. No overall differences in efficacy or safety of telmisartan and amlodipine tablets were observed in this patient population.

Telmisartan Of the total number of patients receiving telmisartan in clinical studies, 551 (18.6%) were 65 to 74 years of age and 130 (4.4%) were 75 years and older. No overall differences in effectiveness and safety were observed in these patients compared to younger patients and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Amlodipine Clinical studies of amlodipine besylate tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

Elderly patients have decreased clearance of amlodipine with a resulting increase of AUC of approximately 40% to 60%, and a lower initial dose may be required. Since patients age 75 and older have decreased clearance of amlodipine, start amlodipine or add amlodipine 2.5 mg to telmisartan. The lowest dose of telmisartan and amlodipine tablet is 40/5 mg; therefore, initial therapy with telmisartan and amlodipine tablet is not recommended in patients 75 years of age and older [see Dosage and Administration (2.5)].

Dosage forms

Philippines

  • Tablet: 40 mg/10 mg, 40 mg/5 mg, 80 mg/10 mg, 80 mg/5 mg
  • Angiotensin ii receptor blocker/ calcium: 80 mg/5 mg
  • Film-coated tablet: 40 mg/5 mg

Registered products in the Philippines

247 products registered with the Food and Drug Administration (FDA) Philippines list Amlodipine + Telmisartan as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products247
Philippine FDA-registered products for Amlodipine + Telmisartan
Package insert
Actarb-ATelmisartan + Amlodipine (as besilate)
40 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Parenterals Ltd.India
Sun Pharma Philippines, Inc.Importer: Nelpa Lifesciences, Inc.
DRP-12942-04
Mar 25, 2030
Actarb-ATelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Parenterals Ltd.#51 TSIIC Industrial Park Hyderabad-Warangal Highway Bhongir Telangana 508116 India
Sun Pharma Philippines, Inc.Importer: Nelpa Lifesciences, Inc.
DRP-11813-08
Mar 25, 2030
Actarb-ATelmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Parenterals Ltd.#51 TSIIC Industrial Park Hyderabad-Warangal Highway Bhongir Telangana 508116 India
Sun Pharma Philippines, Inc.Importer: Nelpa Lifesciences, Inc.
DRP-13376-06
Mar 25, 2030
AmcardisTelmisartan + Amlodipine (As Besilate)
40mg/10mg TabletAlu/Alu Blister Pack x 10's (Box of 10 blister packs x 10 tablets)
RxVAT-exempt
Fredun Pharmaceuticals Limited.India
Amb Hk Enterprises Inc.Importer: AMB HK Enterprises Inc.
DRP-14032
Jun 7, 2028
AmcardisTelmisartan + Amlodipine (As Besilate)
40mg/5mg TabletAlu/Alu Blister Pack x 10's (Box of 10 blister packs x 10 tablets)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
Amb Hk Enterprises Inc.Importer: AMB HK Enterprises Inc.
DRP-14030
Jun 7, 2028
AmcardisTelmisartan + Amlodipine (As Besilate)
80mg/10mg TabletAlu/Alu Blister Pack x 10's (Box of 10 blister packs x 10 tablets)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
Amb Hk Enterprises Inc.Importer: AMB HK Enterprises Inc.
DRP-14033
Jun 7, 2028
AmcardisTelmisartan + Amlodipine (As Besilate)
80mg/5mg TabletAlu/Alu Blister Pack x 10's (Box of 10 blister packs x 10 tablets)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
Amb Hk Enterprises Inc.Importer: AMB HK Enterprises Inc.
DRP-14031
Jun 7, 2028
Amity 40/10Telmisartan + Amlodipine (as besilate)
40 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Zydus Healthcare Philippines, Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12736-05
Sep 30, 2027
Amity 40/5Telmisartan + Amlodipine (as besilate)
40 mg /5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Zydus Healthcare Philippines Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12738-05
Sep 30, 2027
Amity 80/10Telmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Zydus Healthcare Philippines, Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12735-04
Sep 30, 2027
Amity 80/5Telmisartan + Amlodipine (as besilate)
80 mg/ 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Zydus Healthcare Philippines Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12737-05
Sep 30, 2027
AmlotelTelmisartan+ Amlodipine (as Besilate)
40mg/10mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Medinova Pharmaceutical Inc.
DRP-12736
Sep 30, 2027
AmlotelTelmisartan+ Amlodipine (as Besilate)
40mg/5mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Medinova Pharmaceutical Inc.
DRP-12738
Sep 30, 2027
AmlotelTelmisartan+ Amlodipine (as Besilate)
80mg/10mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Medinova Pharmaceutical Inc.
DRP-12735
Sep 30, 2027
AmlotelTelmisartan+ Amlodipine (as Besilate)
80mg/5mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Medinova Pharmaceutical Inc.
DRP-12737
Sep 30, 2027
Amplify 40/10Telmisartan + Amlodipine (as besilate)
40mg/10mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Zydus Healthcare Philippines Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12736-02
Sep 30, 2027
Amplify 40/5Telmisartan + Amlodipine (as besilate)
40mg / 5mg TabletAlu-Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Zydus Healthcare Philippines Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12738-01
Sep 30, 2027
Amplify 80/10Telmisartan + Amlodipine (as besilate)
80mg/10mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Zydus Healthcare Philippines Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12735-01
Sep 30, 2027
Amplify 80/5Telmisartan + Amlodipine (as besilate)
80 mg /5 mg TabletAlu-Alu Blister Pack x 10's. (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Zydus Healthcare Philippines Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12737-03
Sep 30, 2027
Amtera BpTelmisartan + Amlodipine (as besilate)
40 mg/10 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
HLM Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12736-10
Sep 30, 2027
AngicalTelmisartan + Amlodipine (as besilate)
40 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Exemed PharmaceuticalsIndia
AMB HK Enterprises Inc
DRP-16921
Sep 5, 2030
AngicalTelmisartan + Amlodipine (as besilate)
40 mg/5 mg Tablet3 x 10 Alu/Alu Blister Pack
RxVAT-exempt
Exemed PharmaceuticalsIndia
AMB HK Enterprises Inc
DRP-16922
Sep 5, 2030
AngicalTelmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Exemed PharmaceuticalsIndia
AMB HK Enterprises Inc
DRP-16919
Sep 5, 2030
AngicalTelmisartan + Amlodipine (as besilate)
80 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Exemed PharmaceuticalsIndia
AMB HK Enterprises Inc
DRP-16920
Sep 5, 2030
AngiotorTelmisartan + Amlodipine (As Besilate)
40mg/5mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Teramedix Pharma Trading, Inc.Importer: Pharmakon Biotec, Inc.
DRP-15336-09
Jun 24, 2029
Angiotor 80/10Telmisartan + Amlodipine (as Besilate)
80mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-15335-06
Jun 24, 2029
Arb DuoTelmisartan + Amlodipine (as besilate)
40 mg/5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Corona Remedies Pvt. Ltd.India
Iberica Verheilen Pharmaceuticals Group Corp.Importer: Verheilen Iberica Health Care Company, Inc.Trader: Farma Iberica S.L.
DRP-9509
Feb 8, 2031
Besylon PlusTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Medhaus Pharma, Incorporated
DR-XY48862
Aug 31, 2028
BeztelTelmisartan + Amlodipine (as besilate)
40 mg / 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Bulacan
Littman Drug CorporationTrader: Euro-Health Care Exponents, Inc.
DRP-13697-02
Mar 29, 2028
BlitenstaTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister pack x 5's (Box of 30's)
RxVAT-exempt
Inventia Healthcare LimitedIndia
Bliss Pharma Distribution and Consultancy Corp.
DRP-17107
Sep 30, 2030
Blitensta XTelmisartan + Amlodipine (as besilate)
80 mg/ 10 mg TabletAlu/Alu Blister Pack x 5's (Box of 30's)
RxVAT-exempt
Inventia Healthcare LimitedIndia
Bliss Pharma Distribution and Consultancy Corp
DRP-16702
Jun 23, 2030
CardialtaTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Mc Graw Pharma IncImporter: Medinova Pharmaceutical Inc.
DRP-12738-10
Sep 30, 2027
CardialtaTelmisartan + Amlodipine (as besilate)
80 mg / 5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
MC Graw Pharma Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12737-08
Sep 30, 2027
Cilzec ATelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Inventia Healthcare LimitedIndia
Metro Drug, Inc.Importer: Mega Lifesciences Limited Inc.
DRP-16017
Oct 17, 2029
Cilzec-ATelmisartan + Amlodipine (as besilate)
40 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Inventia Healthcare LimitedIndia
Metro Drug, Inc.Importer: Mega Lifesciences Limited Inc.
DRP-16016
Oct 17, 2029
Cilzec-ATelmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Inventia Healthcare LimitedIndia
Metro Drug, Inc.Importer: Mega Lifesciences Limited Inc.
DRP-16014
Oct 17, 2029
Cilzec-ATelmisartan + Amlodipine (as besilate)
80 mg/5 mg Angiotensin II receptor blocker/ CalciumAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Inventia Healthcare LimitedIndia
Metro Drug, Inc.Importer: Mega Lifesciences Limited Inc.
DRP-16015
Oct 17, 2029
Co-MidisTelmisartan + Amlodipine (As Besilate)
80 mg /5 mg TabletAlu/Alu Blister Pack x 10's (Box 30's).
RxVAT-exempt
Standard Chem. & Pharm. Co., Ltd.Taiwan
Standard Chem & Pharm. Philippines, Inc.
DRP-11405
Mar 9, 2027
Corvita 40/10Telmisartan + Amlodipine (as besilate)
40 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc.
DRP-12736-07
Sep 30, 2027
Corvita 40/5Telmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc.
DRP-12738-08
Sep 30, 2027
Corvita 80/10Telmisartan + Amlodipine (as besilate)
80 mg / 10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc.
DRP-12735-07
Sep 30, 2027
Corvita 80/5Telmisartan + Amlodipine (as besilate)
80 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12737-06
Sep 30, 2027
Corzap MaxTelmisartan + Amlodipine (as besilate)
40 mg/10 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Exemed PharmaceuticalsIndia
Helande Kidney Care, Inc.Importer: Amb HK Enterprises, Inc.
DRP-16921-03
Sep 5, 2030
Corzap PlusTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Exemed PharmaceuticalsIndia
Helande Kidney Care, Inc.Importer: AMB HK Enterprises, Inc.
DRP-16922-03
Sep 5, 2030
DuostarTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Dasan Pharmaceutical Co., Ltd.Korea
Justright Healthcare, Inc.
DR-XY47399
Mar 8, 2027
DuostarTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Dasan Pharmaceutical Co., Ltd.Korea
Justright Healthcare, Inc.
DR-XY47401
Mar 8, 2027
LynstaTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
—
DRP-13697
Mar 29, 2028
LynstaTelmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
—
DRP-13696
Mar 29, 2028
MedivascTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Medlink Pharma Phils., Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12738-12
Sep 30, 2027
MisarpinTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Philippine Home Pharmaceuticals
DR-XY49565
Oct 23, 2030
Misarven ATelmisartan + Amlodipine besilate
40 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Inventia Healthcare LimitedIndia
Healol Pharma Corporation
DRP-16759
Jul 11, 2030
Misarven ATelmisartan + Amlodipine besilate
80 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Inventia Healthcare LimitedIndia
Healol Pharma Corporation
DRP-16757
Jul 11, 2030
Misarven ATelmisartan + Amlodipine besilate.
80 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Inventia Healthcare LimitedIndia
Healol Pharma Corporation
DRP-16758
Jul 11, 2030
Mistacor AMTelmisartan + Amlodipine
40 mg/10 mg TabletAlu/Alu Blister Pack x 7's (Box of 7's)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
DRP-11456-01
Mar 16, 2027
Mistacor AMTelmisartan + Amlodipine (as besilate)
80 mg / 5 mg TabletAlu/Alu Blister Pack x 7's (Box of 1 blister pack x 7 tablets)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
DRP-13142-01
Dec 7, 2027
Mistacor AMTelmisartan + Amlodipine (as besilate)
80 mg /10 mg TabletAlu/Alu Blister Pack x 7's (Box of 7's and 28's)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
DRP-15757-02
Oct 4, 2029
Mistacor AMTelmisartan + Amlodipine (as besilate)
80 mg/5 mg TabletAlu/Alu Blister Pack x 7's (Box of 7's)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
DRP-15755-01
Oct 4, 2029
MistasylTelmisartan + Amlodipine (as besilate)
40 mg/ 5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
ECE Pharmaceuticals, Inc.Importer: Nelpa Lifesciences, Inc.
DRP-11813-01
May 2, 2027
MISTASYLTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Innovative HealthcareIndia
ECE Pharmaceuticals, Inc.Importer: Biophil Medical Equipment and Supplies Trading
DRP-17059-01
Oct 7, 2030
MistasylTelmisartan + Amlodipine (as Besilate)
80 mg/ 5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
ECE Pharmaceuticals, Inc.Importer: Nelpa Lifesciences, Inc.
DRP-11424-01
Mar 10, 2027
MistasylTelmisartan + Amlodipine (as besilate)
80 mg/5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Innovative HealthcareIndia
ECE Pharmaceuticals, Inc.Importer: Biophil Medical Equipment and Supplies Trading
DRP-17058-01
Oct 7, 2030
MistralixTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 10 blister packs x 10 tablets)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
Trumed PharmaceuticalsImporter: AMB HK Enterprises Inc.
DRP-14035-01
Jun 7, 2028
Natras DuoTelmisartan + Amlodipine (as besilate)
40 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Innovative HealthcareIndia
Biophil Medical Equipment and Supplies Trading
DRP-17629
Feb 13, 2031
Natras DuoTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Innovative HealthcareIndia
Biophil Medical Equipment and Supplies Trading
DRP-17059
Oct 7, 2030
Natras DuoTelmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Innovative HealthcareIndia
Biophil Medical Equipment and Supplies Trading
DRP-17630
Feb 13, 2031
Natras DuoTelmisartan + Amlodipine (as besilate)
80 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Innovative HealthcareIndia
Biophil Medical Equipment and Supplies Trading
DRP-17058
Oct 7, 2030
NoneTelmisartan + Amlodipine (as besilate)
40 mg / 5 mg TabletAlu/Alu Blister Packs x 10's (Box of 30's)
RxVAT-exempt
Sai Parenterals Ltd.#51 TSIIC Industrial Park Hyderabad-Warangal Highway Bhongir Telangana 508116 India
Actimed, Inc.Importer: Nelpa Lifesciences, Inc.
DRP-11813-09
Mar 25, 2030
NoneTelmisartan + Amlodipine (as besilate)
40 mg / 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Dyna Drug CorporationImporter: Medinova Pharmaceutical Inc.
DRP-12738-14
Sep 30, 2027
NoneTelmisartan + Amlodipine (as besilate)
40 mg / 5 mg TabletAlu/Alu Blister Pack x 7’s (Box of 1 blister pack x 7 tablets)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation
DRP-13059-06
Nov 24, 2027
NoneTelmisartan + Amlodipine (as besilate)
40 mg / 5 mg TabletAlu / Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
St. Joseph DrugstoreTrader: Solvang Pharmaceuticals, Inc.
DRP-14391-01
Aug 31, 2028
NoneTelmisartan + Amlodipine (as besilate)
40 mg/ 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Watsons Personal Care Stores (Philippines), Inc.Trader: Ultramed Pharma Inc.
DRP-15727-01
Aug 14, 2028
NoneTelmisartan + Amlodipine
40 mg/10 mg TabletAlu/Alu Blister Pack x 7's (Box of 4 blister pack x 7 tablets)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
RiteMED Phils., Inc.Importer: Ambica International Corporation
DRP-11456-05
Mar 16, 2027
NoneTelmisartan + Amlodipine (as besilate)
40 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc.
DRP-12942-02
Nov 4, 2027
NoneTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Ambitech Pharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc.
DRP-11813-03
May 2, 2027
NoneTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc.
DRP-11813-05
May 2, 2027
NoneTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 7's (Box of 4 blister pack x 7 tablets)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
RiteMED Phils., Inc.Importer: Ambica International Corporation
DRP-13059-07
Nov 24, 2027
NoneTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
South Star DrugTrader: Innogen Pharmaceuticals, Inc.
DRP-14393-01
Aug 31, 2028
NoneTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Rose Pharmacy, IncorporatedTrader: Innogen Pharmaceuticals, Inc.
DRP-14393-02
Aug 31, 2028
NoneTelmisartan + Amlodipine (as besilate)
80 mg / 10 mgAlu/Alu Blister Pack x 10’s (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Dyna Drug CorporationImporter: Medinova Pharmaceutical Inc.
DRP-12735-10
Sep 30, 2027
NoneTelmisartan + Amlodipine (as besilate)
80 mg / 5 mg TabletAlu/Alu Blister Pack x 7's (Box of 4 blister pack x 7 tablets)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
RiteMED Phils., Inc.Importer: Ambica International Corporation
DRP-13142-05
Dec 7, 2027
NoneTelmisartan + Amlodipine (as besilate)
80 mg/ 10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Watsons Personal Care Stores (Philippines), Inc.Trader: Ultramed Pharma Inc.
DRP-15737-01
Aug 10, 2028
NoneTelmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 7’s (Box of 1 blister pack x 7 tablets)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation
DRP-13089-05
Nov 28, 2027
NoneTelmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 7's (Box of 4 blister pack x 7 tablets)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
RiteMed Phils., Inc.Importer: Ambica International Corporation
DRP-13089-06
Nov 28, 2027
NoneTelmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Packs x 10's (Box of 3 blister packs x 10 tablets)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Ambitech Pharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc.
DRP-13376-02
Feb 8, 2028
NoneTelmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 3 blister packs x 10 tablets)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc.
DRP-13376-03
Feb 8, 2028
NoneTelmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
South Star DrugTrader: Innogen Pharmaceuticals, Inc.
DRP-14392-01
Aug 31, 2028
NoneTelmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Rose Pharmacy, IncorporatedTrader: Innogen Pharmaceuticals, Inc.
DRP-14392-02
Aug 31, 2028
NoneTelmisartan + Amlodipine (as besilate)
80 mg/5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Watsons Personal Care Store (Philippines), Inc.Importer: Nelpa Lifesciences, Inc.
DRP-11424-02
Mar 10, 2027
NoneTelmisartan + Amlodipine (as besilate)
80 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc.
DRP-11424-04
Mar 10, 2027
NoneTelmisartan + Amlodipine (as besilate)
80 mg/5 mg TabletAlu/Alu Blister Pack x 7’s (Box of 1 blister pack x 7 tablets); Alu/Alu Blister Pack x 7’s (Box of 4 blister pack x 7 tablets); Alu/Alu Blister Pack x 7’s (Box of 14 blister pack x 7 tablets)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation
DRP-13142-04
Dec 7, 2027
ProtelmisarpineTelmisartan + Amlodipine (as besilate)
40 mg/ 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Parenterals Ltd.India
Providencia Medica Inc.Importer: Nelpa Lifesciences, Inc.
DRP-11813-10
Mar 25, 2030
Retatel Plus 40/10Telmisartan + Amlodipine (as besilate)
40 mg/10 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Reta DrugImporter: Medinova Pharmaceutical Inc.
DRP-12736-09
Sep 30, 2027
Retatel Plus 40/5Telmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Reta DrugImporter: Medinova Pharmaceutical Inc.
DRP-12738-11
Sep 30, 2027
Retatel Plus 80/10Telmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu / Alu Blister Pack x 10’s (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Reta DrugImporter: Medinova Pharmaceutical Inc.
DRP-12735-09
Sep 30, 2027
Retatel Plus 80/5Telmisartan + Amlodipine (as besilate)
80 mg/5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Reta DrugImporter: Medinova Pharmaceutical Inc.
DRP-12737-09
Sep 30, 2027
Saphtelo-G45Telmisartan +Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Genom Biotech Pvt. Ltd.India
Nelpa Lifesciences, Inc
DRP-17413
Dec 12, 2030
Saphtelo-G50Telmisartan +Amlodipine (as besilate)
40 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Genom Biotech Pvt. Ltd.India
Nelpa Lifesciences, Inc
DRP-17412
Dec 12, 2030
Saphtelo-G85Telmisartan +Amlodipine (as besilate)
80 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Genom Biotech Pvt. Ltd.India
Nelpa Lifesciences, Inc
DRP-17411
Dec 12, 2030
Saphtelo-G90Telmisartan +Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Genom Biotech Pvt. Ltd.India
Nelpa Lifesciences, Inc
DRP-17410
Dec 12, 2030
SarTamTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories Inc.Philippines
Heltker A.G. Corporation
DR-XY49423
Jun 24, 2030
SarTamTelmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories Inc.Philippines
Heltker A.G. Corporation
DR-XY49422
Jul 1, 2030
SynergiaTelmisartan + Amlodipine (as besilate)
40 mg/10 mg TabletAlu/Alu Blister Pack x 10s (Box of 30's)
RxVAT-exempt
Dasan Pharmaceutical Co., Ltd.Republic of Korea
UNILAB , Inc.
DRP-10131
Jul 29, 2031
SynergiaTelmisartan + Amlodipine (as besilate)
80 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Dasan Pharmaceutical Co., Ltd.Republic of Korea
UNILAB , Inc.
DRP-10132
Jul 29, 2031
Syntam 40/10Telmisartan + Amlodipine (as besilate)
40 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Zydus Healthcare Philippines, Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12736-06
Sep 30, 2027
Syntam 40/5Telmisartan + Amlodipine (as besilate)
40 mg /5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Zydus Healthcare Philippines Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12738-07
Sep 30, 2027
Syntam 80/10Telmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Zydus Healthcare Philippines, Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12735-05
Sep 30, 2027
Syntam 80/5Telmisartan + Amlodipine (as besilate)
80 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Zydus Healthcare Philippines Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12737-04
Sep 30, 2027
TAMILOPIN-40Telmisartan + Amlodipine (Besilate)
40 mg/5mg TabletAlu/Alu Blister Pack X 10’s (Box of 30's)
RxVAT-exempt
Genuone Sciences Inc.Republic of Korea
Bellus Life Solutions, Inc.
DRP-9171
Sep 25, 2030
Tamilopin-80Telmisartan + Amlodipine (Besilate)
80 mg/5 mg TabletAlu/Alu Blister Pack X 10’s (Box of 30's)
RxVAT-exempt
Genuone Sciences Inc.Republic of Korea
Bellus Life Solutions, Inc.
DRP-9172
Sep 25, 2030
Tarsina PlusTelmisartan + Amlodipine (as besilate)
40 mg/ 5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Exemed PharmaceuticalsIndia
Lakeside Pharmaceuticals Phil., Inc.Importer: AMB HK Enterprises Inc.
DRP-16922-04
Sep 5, 2030
Tarsina PlusTelmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Exemed PharmaceuticalsIndia
Lakeside Pharmaceuticals Phil., Inc.Importer: AMB HK Enterprises Inc.
DRP-16919-04
Sep 5, 2030
Team DuoTelmisartan + Amlodipine (as besilate)
40 mg / 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Pharma Hub CorporationImporter: Nelpa Lifesciences, Inc.
DRP-11813-04
May 2, 2027
Team DuoTelmisartan + Amlodipine (as besilate)
40 mg / 5 mg TabletAlu/Alu Blister Pack x 7’s (Box of 7’s)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Pharma Hub CorporationImporter: Ambica International Corporation
DRP-15758-01
Oct 4, 2029
Team DuoTelmisartan + Amlodipine (as besilate)
40 mg/ 5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Exemed PharmaceuticalsIndia
Pharma Hub CorporationImporter: AMB HK Enterprises Inc.
DRP-16922-02
Sep 5, 2030
Team DuoTelmisartan + Amlodipine (as besilate)
40 mg/10 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Exemed PharmaceuticalsIndia
Pharma Hub CorporationImporter: AMB HK Enterprises Inc.
DRP-16921-02
Sep 5, 2030
Team DuoTelmisartan + Amlodipine (as besilate)
80 mg / 5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Exemed PharmaceuticalsIndia
Pharma Hub CorporationImporter: AMB HK Enterprises Inc.
DRP-16920-02
Sep 5, 2030
Team DuoTelmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Packs x 10's (Box of 3 blister packs x 10 tablets)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Pharma Hub CorporationImporter: Nelpa Lifesciences, Inc.
DRP-13376-04
Feb 8, 2028
Team DuoTelmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 7’s (Box of 7’s)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Pharma Hub CorporationImporter: Ambica International Corporation
DRP-15757-01
Oct 4, 2029
Team DuoTelmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Exemed PharmaceuticalsIndia
Pharma Hub CorporationImporter: Amb Hk Enterprises Inc.
DRP-16919-02
Sep 5, 2030
TEL-AMLO 40Telmisartan + Amlodipine (Besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Genuone Sciences Inc.Republic of Korea
Aglobal Care, Inc.Importer: Bellus Life Solutions, Inc.
DRP-9171-01
Oct 30, 2031
Tel-Amlo 80Telmisartan + Amlodipine (Besilate)
80 mg/5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Genuone Sciences Inc.Republic of Korea
Aglobal Care, Inc.Importer: Bellus Life Solutions, Inc.
DRP-9172-01
Oct 17, 2031
TelamTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, IncPhilippines
Trader: Corbridge Group Phils., Inc.
DRP-18257
Jun 4, 2031
TelamedTelmisartan + Amlodipine (as besylate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Flourish PharmaIndia
Speed Med Pharmaceuticals, Inc.Importer: Biophil Medical Equipment and Supplies Trading
DRP-16491
Jun 3, 2030
Telarb CCBTelmisartan + Amlodipine (as besilate)
40 mg / 10 mg TabletAlu-Alu Blister Pack x 10's. (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
The Cathay YSS Distributors Co., Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12736-04
Sep 30, 2027
Telarb CCBTelmisartan + Amlodipine (as besilate)
40mg/5mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
The Cathay YSS Distributors Co., Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12738-04
Sep 30, 2027
Telarb CCBTelmisartan + Amlodipine (as besilate)
80 mg / 5 mg TabletAlu-Alu Blister Pack x 10's. (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
The Cathay YSS Distributors Co., Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12737-01
Sep 30, 2027
Telarb CCBTelmisartan + Amlodipine (as besilate)
80mg/10mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
The Cathay YSS Distributors Co., Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12735-03
Sep 30, 2027
Telday Amlo 40/5Telmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Parenterals Ltd.#51 TSIIC Industrial Park Hyderabad-Warangal Highway Bhongir Telangana 508116 India
Torrent Pharma Philippines, Inc.Importer: Nelpa Lifesciences, Inc.
DRP-11813-07
Mar 25, 2030
Telday Amlo 80/10Telmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Parenterals Ltd.#51 TSIIC Industrial Park Hyderabad-Warangal Highway Bhongir Telangana 508116 India
Torrent Pharma Philippines, Inc.Importer: Nelpa Lifesciences, Inc.
DRP-13376-07
Mar 25, 2030
Telday Amlo 80/5Telmisartan + Amlodipine (as besilate)
80 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Parenterals Ltd.TSIIC Industrial Park Hyderabad-Warangal Highway Bhongir Telangana 508116 India
Torrent Pharma Philippines, Inc.Importer: Nelpa Lifesciences, Inc.
DRP-11424-05
Jul 3, 2030
Telfort AM 40/5Telmisartan + Amlodipine (as besilate)
40 mg /5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Exemed PharmaceuticalsIndia
PH Phil Asia Medica Co.Importer: AMB HK Enterprises Inc.
DRP-16922-06
Sep 5, 2030
Telfort AM 80/10Telmisartan + Amlodipine (as besilate)
80 mg /10 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Exemed PharmaceuticalsIndia
PH Phil Asia Medica Co.Importer: AMB HK Enterprises Inc.
DRP-16919-05
Sep 5, 2030
Telgrand-AmTelmisartan + Amlodipine (as besilate)
40 mg / 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Grandis Pharma IncorporatedImporter: Pharmakon Biotec Inc.
DRP-15336-07
Jun 24, 2029
TeliDril 40 ProTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Aldril Pharmaceuticals, Inc.
DRP-14395
Aug 31, 2028
TeliDril 80 ProTelmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Aldril Pharmaceuticals, Inc.
DRP-14394
Aug 31, 2028
TeliGen-40 ProTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Innogen Pharmaceuticals, Inc.
DRP-14393
Aug 31, 2028
TeliGen-80 Pro.Telmisartan + Amlodipine (as besilate).
80 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Innogen Pharmaceuticals, Inc.
DRP-14392
Aug 31, 2028
TeliSolv ProTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Solvang Pharmaceuticals, Inc.
DRP-14391
Aug 31, 2028
TeliSolv ProTelmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Solvang Pharmaceuticals, Inc.
DRP-14390
Aug 31, 2028
TelmalTelmisartan + Amlodipine (as besilate)
40 mg / 5 mg TabletAlu-Alu Blister Pack x 10's. (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Britton Distributions, Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12738-02
Sep 30, 2027
TelmalTelmisartan + Amlodipine (as besilate)
40mg/10mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Britton Distributions, Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12736-03
Sep 30, 2027
TelmalTelmisartan + Amlodipine (as besilate)
80 mg / 10 mg TabletAlu-Alu Blister Pack x 10's. (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Britton Distributions, Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12735-02
Sep 30, 2027
TelmalTelmisartan + Amlodipine (as besilate)
80mg/5mg TabletAlu-Alu Blister Pack x 10's. (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Britton Distributions, Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12737-02
Sep 30, 2027
Telmefixx PlusTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 7’s (Box of 4 Blister Pack x 7 Tablets)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
D&G PharmaImporter: Ambica International Corporation
DRP-13059-02
Nov 24, 2027
Telmez CCBTelmisartan + Amlodipine (as besilate)
40 mg / 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines Inc.
DRP-16240
Oct 31, 2029
Telmez CCBTelmisartan + Amlodipine (as besilate)
40 mg /10 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30's)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Ajanta Pharma Philippines IncImporter: Nelpa Lifesciences, Inc.
DRP-12942-01
Nov 4, 2027
Telmez CCBTelmisartan + Amlodipine (as besilate)
40 mg /10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines Inc.
DRP-16238
Oct 31, 2029
Telmez CCBTelmisartan + Amlodipine (as besilate)
40 mg /5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30's)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Ajanta Pharma Philippines IncImporter: Nelpa Lifesciences, Inc.
DRP-11813-02
May 2, 2027
Telmez CCBTelmisartan + Amlodipine (as besilate)
40 mg/ 10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines Inc.Importer: Ajanta Pharma Philippines Inc..
DR-XY49263
Oct 31, 2029
Telmez CCBTelmisartan + Amlodipine (as besilate)
40 mg/ 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines Inc.Importer: Ajanta Pharma Philippines Inc..
DR-XY49264
Oct 31, 2029
Telmez CCBTelmisartan + Amlodipine (as Besilate)
80 mg / 10 mg TabletAlu-Alu Blister Pack of 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines Inc.
DRP-16237
Jul 5, 2029
Telmez CCBTelmisartan + Amlodipine (as Besilate)
80 mg / 5 mg TabletAlu-Alu Blister Pack of 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines Inc.
DRP-16239
Oct 21, 2029
Telmez CCBTelmisartan + Amlodipine (as besilate)
80 mg /10 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Ajanta Pharma Philippines IncImporter: Nelpa Lifesciences, Inc.
DRP-13376-01
Feb 8, 2028
TELMEZ CCBTelmisartan + Amlodipine (as besilate)
80 mg /5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30's)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Ajanta Pharma Philippines Inc.Importer: Nelpa Lifesciences, Inc.
DRP-11424-03
Mar 10, 2027
Telmez CCBTelmisartan + Amlodipine (as Besilate)
80 mg/10 mg TabletAlu-Alu Blister Pack of 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines Inc.Importer: Ajanta Pharma Philippines Inc..
DR-XY49122
Jul 5, 2029
Telmez CCBTelmisartan + Amlodipine (as Besilate)
80 mg/5 mg TabletBlister Pack of 10's (Box of 30's) s (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines Inc.Importer: Ajanta Pharma Philippines Inc..
DR-XY49255
Oct 21, 2029
Telmicass PlusTelmisartan + Amlodipine (as besilate)
40 mg / 10 mg TabletAlu-Alu Blister Pack of 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Cassandras Care Pharmaceutical DistributorImporter: Medinova Pharmaceutical Inc.
DRP-12736-1
Sep 30, 2027
Telmicass PlusTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Cassandras Care Pharmaceutical DistributorImporter: Medinova Pharmaceutical Inc.
DRP-12738-13
Sep 30, 2027
Telmifer+Telmisartan + Amlodipine (as besilate)
40 mg/ 5 mg TabletAlu / Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Ferma Drug EnterprisesImporter: Pharmakon Biotec Inc.
DRP-15336-08
Jun 24, 2029
Telmiget DuoTelmisartan + Amlodipine
40 mg/ 10 mg TabletAlu/Alu Blister Pack x 7's (Box of 28's and 98's)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Getz Pharma (Phils.), Inc.Importer: Ambica International Corporation
DRP-11456-03
Mar 16, 2032
Telmiget DuoTelmisartan + Amlodipine (as besilate)
40 mg/ 5 mg TabletAlu/Alu Blister Pack x 7’s (Box of 1 blister pack x 7 tablets)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Getz Pharma (Phils.), Inc.Importer: Ambica International Corporation
DRP-13059-04
Nov 24, 2027
Telmiget DuoTelmisartan + Amlodipine (as besilate)
80 mg/ 10 mg TabletAlu/Alu Blister Pack x 7’s (Box of 14 blister pack x 7 tablets)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Getz Pharma (Phils.), Inc.Importer: Ambica International Corporation
DRP-13089-03
Nov 28, 2027
Telmiget DuoTelmisartan + Amlodipine (as besilate)
80 mg/ 5 mg TabletAlu/Alu Blister Pack x 7’s (Box of 14 blister pack x 7 tablets)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Getz Pharma (Phils.), Inc.Importer: Ambica International Corporation
DRP-13142-03
Dec 7, 2027
Telmikem-AmTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Alkem Laboratories CorporationImporter: Pharmakon Biotec Inc.
DRP-15336-01
Jun 24, 2029
TelmilifeTelmisartan + Amlodipine (as besilate)
40 mg/ 5 mg TabletAlu / Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
One Technodrug Life Sciences Inc.Importer: Pharmakon Biotec Inc.
DRP-15336-04
Jun 24, 2029
TelmilifeTelmisartan + Amlodipine (as besilate)
80 mg/ 10 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
One Technodrug Life Sciences Inc.Importer: Pharmakon Biotec Inc.
DRP-15335-03
Jun 24, 2029
TelmilopTelmisartan + Amlodipine
40 mg / 10 mg TabletAlu/Alu Blister Pack x 7's (Box of 7's)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-11456
Mar 16, 2027
TelmilopTelmisartan + Amlodipine (as besilate)
40 mg/ 5 mg TabletAngiotensin II Receptor Blockers (ARBS) and Calcium Channel Blocker
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-13059
Nov 24, 2027
TelmilopTelmisartan + Amlodipine (as besilate)
80 mg / 10 mg TabletAlu/Alu Blister Pack x 7's (Box of 1 blister pack x 10 tablets)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-13089
Nov 28, 2027
TelmilopTelmisartan + Amlodipine (as besilate)
80 mg / 5 mg TabletAlu/Alu Blister Pack x 7's (Box of 1 blister pack x 7 tablets)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-13142
Dec 7, 2027
TelmimoreTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Alternative Platform Exchange, Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12738-06
Sep 30, 2027
TelmimoreTelmisartan + Amlodipine (as besilate)
80mg/10mg TabletAlu-Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Alternative Platform Exchange, Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12735-06
Sep 30, 2027
TelmipinTelmisartan + Amlodipine (as besilate)
40 mg/ 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Ultramed Pharma Inc.
DRP-15727
Aug 14, 2028
TelmipinTelmisartan + Amlodipine (As Besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Ultramed Pharma, Inc.
DR-XY48847
Aug 14, 2028
TelmipinTelmisartan + Amlodipine(as besilate)
80 mg/ 10 mg TabletAlu/Alu Blister Pack x 10'S (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Ultramed Pharma, Inc.
DR-XY48844
Aug 10, 2028
TelmipinTelmisartan + Amlodipine (as besilate)
80 mg/ 10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Ultramed Pharma Inc.
DRP-15737
Aug 10, 2028
Telmiprem PlusTelmisartan + Amlodipine (as besilate)
40 mg / 5 mg TabletAlu/ Alu Blister Pack x 10’s (Box of 100’s)
RxVAT-exempt
Exemed PharmaceuticalsIndia
Premier Pharmaceuticals Marketing Corp.Importer: AMB HK Enterprises Inc.
DRP-16922-05
Sep 5, 2030
Telmiprem PlusTelmisartan + Amlodipine (as besilate)
40 mg/ 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 10 blister packs x 10 tablets)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
Premier Pharmaceuticals Marketing Corp.Importer: AMB HK Enterprises Inc.
DRP-14030-01
Jun 7, 2028
Telmiprem PlusTelmisartan + Amlodipine (as besilate)
80 mg/ 10 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s)
RxVAT-exempt
Exemed PharmaceuticalsIndia
Premier Pharmaceuticals Marketing Corp.Importer: AMB HK Enterprises Inc.
DRP-16919-03
Sep 5, 2030
Telmirx PlusTelmisartan + Amlodipine (As Besilate)
40mg/10mg TabletAngiotensin II Receptor Blocker Channel Blocker
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
Amb Hk Enterprises Inc.Importer: AMB HK Enterprises Inc.
DRP-14036
Jun 7, 2028
Telmirx PlusTelmisartan + Amlodipine (As Besilate)
40mg/5mg TabletAlu/Alu Blister Pack x 10's (Box of 10 blister packs x 10 tablets)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
AmB HK Enterprises Inc.Importer: AMB HK Enterprises Inc.
DRP-14035
Jun 7, 2028
Telmirx PlusTelmisartan + Amlodipine (As Besilate)
80mg/10mg TabletAluminium/Aluminium blister pack
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
Amb Hk Enterprises Inc.Importer: AMB HK Enterprises Inc.
DRP-14037
Jun 7, 2028
Telmirx PlusTelmisartan + Amlodipine (As Besilate)
80mg/5mg TabletAlu/Alu Blister Pack x 10's (Box of 10 blister packs x 10 tablets)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
Amb Hk Enterprises Inc.Importer: AMB HK Enterprises Inc.
DRP-14034
Jun 7, 2028
Telmisaph-A45Telmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Packs x 10's (Box of 30's)
RxVAT-exempt
Sai Parenterals Ltd.India
Nelpa Lifesciences, Inc.,
DRP-11813
Mar 25, 2030
Telmisaph-A50Telmisartan + Amlodipine (As Besylate)
40mg/10mg TabletAlu/Alu blister pack x 10's (Box of 30's)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Nelpa Lifesiences, Inc.
DRP-12942
Nov 4, 2027
Telmisaph-A85Telmisartan + Amlodipine (as besilate)
80 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Parenterals Ltd.India
Nelpa Lifesciences Inc.
DRP-11424
Jul 3, 2030
Telmisaph-A90Telmisartan + Amlodipine (as besilate)
80mg/10mg TabletAlu/ Alu Blister Packs × 10’ s (Box of 3 blister packs × 10 tablets)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-13376
Feb 8, 2028
Telmisar AMTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Mediwin PharmaceuticalsIndia
Euroasia Pharmaceuticals, Inc.Trader: Tunic Healthcare
DRP-13616
Mar 17, 2028
Telmisar AM- 80Telmisartan + Amlodipine (as besilate)
80 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Mediwin PharmaceuticalsIndia
Euroasia Pharmaceuticals, Inc.Trader: Tunic Healthcare
DRP-13269
Jan 20, 2028
Telmistal AM 45Telmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-19162
Nov 11, 2031
Telmistal AM 85Telmisartan + Amlodipine (as besilate)
80 mg/5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-19163
Nov 11, 2031
Telmistal AM 90Telmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-19164
Nov 11, 2031
Telmix 45Telmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
K Pharma Medical Corp.Importer: Medinova Pharmaceutical Inc
DRP-12738-03
Sep 30, 2027
TELMLOSPAR-85Telmisartan + Amlodipine
80 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Alwin DMD PharmaceuticalsIndia
Aspar Pharmaceutical Inc.
DRP-16567
Apr 29, 2030
TelovascTelmisartan + Amlodipine (as besilate)
40 mg / 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
C.B. HEALTHCAREIndia
Pranish, Inc
DR-XY49811
Sep 29, 2031
Telpine-AMTelmisartan + Amlodipine (as besilate)
40 mg / 5 mg TabletAlu / Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
RoDaise Pharma Distributor CorporationImporter: Pharmakon Biotec Inc.
DRP-15336-06
Jun 24, 2029
Telpine-AMTelmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu / Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
RoDaise Pharma Distributor CorporationImporter: Pharmakon Biotec Inc.
DRP-15335-01
Jun 24, 2029
Telstar Duo®Telmisartan + Amlodipine (as besilate)
40 mg/ 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
GX International, Inc.Trader: Euro-Health Care Exponents, Inc.
DRP-13697-01
Mar 29, 2028
Telstar Duo®Telmisartan + Amlodipine (as besilate)
80 mg/ 10 mg TabletAlu /Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
GX International, Inc.Trader: Euro-Health Care Exponents, Inc.
DRP-13696-01
Mar 29, 2028
TelvascTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Rule Med Pharma Corp.Importer: Pharmakon Biotec, Inc.
DRP-15336-10
Jun 24, 2029
TelzarpinTelmisartan + Amlodipine (as besilate)
40 mg/10 mg TabletAlu/Alu Blister Pack x 7's (Box of 7's)
RxVAT-exempt
Titan Laboratories Pvt. LtdIndia
Ambica International Corporation
DRP-15756
Oct 4, 2029
TelzarpinTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 7's (Box of 7's)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-15758
Oct 4, 2029
TelzarpinTelmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 7's (Box of 7's)
RxVAT-exempt
Titan Laboratories Pvt. LtdIndia
Ambica International Corporation
DRP-15757
Oct 4, 2029
TelzarpinTelmisartan + Amlodipine (as besilate)
80 mg/5 mg TabletAlu/Alu Blister Pack x 7's (Box of 7's)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-15755
Oct 4, 2029
TemstaTelmisartan + Amlodipine (as besilate)
40 mg / 5 mg TabletAlu/Alu Blister Pack x 7's (Box of 4 blister pack x 7 tablets)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Uni-Pharma Phils., Inc.Importer: Ambica International Corporation
DRP-13059-03
Nov 24, 2027
TemstaTelmisartan + Amlodipine
40 mg/ 10 mg TabletAlu/Alu Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Uni-Pharma Phils., Inc.Importer: Ambica International Corporation
DRP-11456-02
Mar 16, 2032
TemstaTelmisartan + Amlodipine (as besilate)
80 mg / 10 mg TabletAlu/Alu Blister Pack x 7’s (Box of 4 blister pack x 7 tablets)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Uni-Pharma Phils., Inc.Importer: Ambica International Corporation
DRP-13089-02
Nov 28, 2027
TemstaTelmisartan + Amlodipine (as besilate)
80 mg/ 5 mg TabletAlu/Alu Blister Pack x 7’s (Box of 4 blister pack x 7 tablets)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Uni-Pharma Phils., Inc.Importer: Ambica International Corporation
DRP-13142-02
Dec 7, 2027
TeprivaTelmisartan + Amlodipine (as besilate)
40mg/5mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
The Acme Laboratories LimitedBangladesh
Bell-Kenz Pharma, Inc.Importer: Euro Generics International Phils., Inc.
DR-XY49469
Aug 8, 2031
TeprivaTelmisartan + Amlodipine (as besilate)
80mg/5mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
The Acme Laboratories LimitedBangladesh
Euro Generics International Phils., Inc.
DR-XY49468
Aug 8, 2031
Tevex-A40/5Telmisartan + Amlodipine (as besilate)
40mg/5mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
East African (India) OverseasIndia
VE Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd.
DR-XY49680
Mar 24, 2031
Tevex-A80/10Telmisartan + Amlodipine (as besilate)
80mg/10mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
East African (India) OverseasIndia
VE Pharma Inc.Trader: Vexxa Lifesciences Limited
DR-XY49511
Sep 11, 2030
Tevex-A80/5Telmisartan + Amlodipine (as besilate)
80mg/5mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
East African (India) OverseasIndia
VE Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd.
DR-XY49679
Mar 24, 2031
Tezart 80/10Telmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's, 60's and 100's)
RxVAT-exempt
Nabros Pharma Pvt. Ltd.India
Despina Pharma, Inc.
DRP-17078
Sep 23, 2030
TwynstaTelmisartan + Amlodipine (as Besilate)
40 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cipla Ltd. (Unit IV)India
Importer: Boehringer Ingelheim (Philippines), Inc.
DRP-7256
Feb 16, 2031
TwynstaTelmisartan + Amlodipine (as Besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cipla Ltd. (Unit IV)India
Importer: Boehringer Ingelheim (Philippines), Inc.
DRP-7255
Feb 16, 2031
TwynstaTelmisartan + Amlodipine (as Besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cipla Ltd. (Unit IV)India
Importer: Boehringer Ingelheim (Philippines), Inc.
DRP-7443
Feb 16, 2031
TwynstaTelmisartan + Amlodipine (as Besilate)
80 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cipla Ltd. (Unit IV)India
Boehringer Ingelheim (Philippines), Inc.
DRP-7254
Feb 16, 2031
UnbrandedTelmisartan + Amlodipine
40 mg/10 mg TabletAlu/Alu Blister Pack x 7's (Box of 7’s and Box of 28's)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
Watsons Personal Care Stores (Philippines), Inc.Importer: Ambica International Corporation
DRP-11456-04
Mar 16, 2032
ValuganTelmisartan + Amlodipine (as besilate)
40 mg / 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 10 blister packs x 10 tablets)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
Corbridge Group Phils., Inc.Importer: AMB HK Enterprises Inc.
DRP-14035-02
Jun 7, 2028
ValuganTelmisartan + Amlodipine (as besilate)
40 mg/ 10 mg TabletAlu / Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Exemed PharmaceuticalsIndia
Corbridge Group Phils., Inc.Importer: AMB HK Enterprises Inc.
DRP-16921-01
Sep 5, 2030
ValuganTelmisartan + Amlodipine (as besilate)
40 mg/ 5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Exemed PharmaceuticalsIndia
Corbridge Group Phils., Inc.Importer: AMB HK Enterprises Inc.
DRP-16922-01
Sep 5, 2030
ValuganTelmisartan + Amlodipine (as besilate)
40 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 10 blister packs x 10 tablets)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
Corbridge Group Phils., Inc.Importer: AMB HK Enterprises Inc.
DRP-14036-01
Jun 7, 2028
ValuganTelmisartan + Amlodipine (as besilate)
80 mg /10 mg TabletAlu/Alu Blister Pack x 10's (Box of 10 blister packs x 10 tablets)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
Corbridge Group Phil., Inc.Importer: AMB Hk Enterprises Inc.
DRP-14037-01
Jun 7, 2028
ValuganTelmisartan + Amlodipine (as besilate)
80 mg/ 10 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Exemed PharmaceuticalsIndia
Corbridge Group Phils., Inc.Importer: AMB HK Enterprises Inc.
DRP-16919-01
Sep 5, 2030
ValuganTelmisartan + Amlodipine (as besilate)
80 mg/ 5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Exemed PharmaceuticalsIndia
Corbridge Group Phils., Inc.Importer: AMB HK Enterprises Inc.
DRP-16920-01
Sep 5, 2030
ValuganTelmisartan + Amlodipine (as besilate)
80 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 10 blister packs x 10 tablets)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
Corbridge Group Phils., Inc.Importer: AMB HK Enterprises Inc.
DRP-14034-01
Jun 7, 2028
VasatrazTelmisartan + Amlodipine (as besilate)
40 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Alembic Pharmaceuticals LimitedIndia
Natrapharm Inc.
DR-XY49480
Aug 29, 2030
VasatrazTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Alembic Pharmaceuticals LimitedIndia
Natrapharm Inc.
DR-XY49481
Aug 29, 2030
VasatrazTelmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Alembic Pharmaceuticals LimitedIndia
Natrapharm Inc.
DR-XY49478
Aug 29, 2030
VasatrazTelmisartan + Amlodipine (as besilate)
80 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Alembic Pharmaceuticals LimitedIndia
Natrapharm Inc.
DR-XY49479
Aug 29, 2030
VasoduoTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Sigmamatic Co. Inc.Importer: Pharmakon Biotec Inc.
DRP-15336-03
Jun 24, 2029
VasoduoTelmisartan + Amlodipine (as besilate)
80 mg /10 mg TabletAlu / Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Sigmamatic Co. Inc.Importer: Pharmakon Biotec Inc.
DRP-15335-02
Jun 24, 2029
Vasotrel 80 PlusTelmisartan + Amlodipine (as Besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Kwality Pharmaceuticals Ltd.India
Pharma-Surrey International Inc.
DRP-17244
Oct 24, 2030
Zamplify 40/10Telmisartan + Amlodipine (as besilate)
40 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Zydus Healthcare Philippines, Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12736-08
Sep 30, 2027
Zamplify 40/5Telmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Zydus Healthcare Philippines, Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12738-09
Sep 30, 2027
Zamplify 80/10Telmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Zydus Healthcare Philippines, Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12735-08
Sep 30, 2027
Zamplify 80/5Telmisartan + Amlodipine (as besilate)
80 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Zydus Healthcare Philippines, Inc.Importer: Medinova Pharmaceutical Inc.
DRP-12737-07
Sep 30, 2027
Zardip DuoTelmisartan + Amlodipine (as besilate)
40 mg/ 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-15336-05
Jun 24, 2029
Zardip DuoTelmisartan + Amlodipine (as besilate)
80 mg/ 10mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-15335-04
Jun 24, 2029
ZenoviaTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Parenterals Ltd.India
TGP Pharma Inc.Importer: Nelpa Lifesciences, Inc.
DRP-11813-06
Mar 25, 2030
ZenoviaTelmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 7’s (Box of 1 blister pack x 7 tablets); Alu/Alu Blister Pack x 7’s (Box of 4 blister pack x 7 tablets)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
TGP Pharma Inc.Importer: Ambica International Corporation
DRP-13059-05
Nov 24, 2027
ZenoviaTelmisartan + Amlodipine (as besilate)
80 mg / 10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sai Parenterals Ltd.India
TGP Pharma Inc.Importer: Nelpa Lifesciences, Inc.
DRP-13376-05
Mar 25, 2030
ZenoviaTelmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 7’s (Box of 1 blister pack x 7 tablets); Alu/Alu Blister Pack x 7’s (Box of 4 blister pack x 7 tablets)
RxVAT-exempt
Titan Laboratories Pvt. Ltd.India
TGP Pharma Inc.Importer: Ambica International Corporation
DRP-13089-04
Nov 28, 2027
Zermisar Plus 40/5Telmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Hale Medipoint Corp.Importer: Pharmakon Biotec Inc.
DRP-15336-02
Jun 24, 2029
(no brand name)Telmisartan + Amlodipine (as besilate)
40 mg/5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Dr. Zen's Research, Inc.
DRP-14397
Aug 31, 2028
(no brand name)Telmisartan + Amlodipine (as besilate)
80 mg/10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Dr. Zen's Research, Inc.
DRP-14396
Aug 31, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS 40 mg/5 mg: Oval shaped biconvex, bilayer, uncoated tablets with one white to off white color layer and one blue color mottled layer debossed with ‘L389’. 40 mg/10 mg: Oval shaped biconvex, bilayer, uncoated tablets with one white to off white color layer and one blue color mottled layer debossed with ‘L390’. 80 mg/5 mg: Oval shaped biconvex, bilayer, uncoated tablets with one white to off white color layer and one blue color mottled layer debossed with ‘L39l’. 80 mg/10 mg: Oval shaped biconvex, bilayer, uncoated tablets with one white to off white color layer and one blue color mottled layer debossed with ‘L388’. Tablets: 40 mg/5 mg, 40 mg/10 mg, 80 mg/5 mg, 80 mg/10 mg (3)

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label
  • Avoid fetal or neonatal exposure (5.1)
  • Hypotension: Correct any volume or salt depletion before initiating therapy. Observe for signs and symptoms of hypotension. Symptomatic hypotension is possible, particularly in patients with severe aortic stenosis (5.2)
  • Titrate slowly in patients with hepatic (5.4)
  • or severe renal impairment (5.5)
  • Heart failure: Monitor for worsening (5.8)
  • Avoid concomitant use with an ACE inhibitor (5.6)
  • Myocardial infarction: Worsening angina and acute myocardial infarction can develop after starting or increasing the dose of telmisartan and amlodipine tablets, particularly in patients with severe obstructive coronary artery disease (5.7).
5.1 Fetal Toxicity

5.1 Fetal Toxicity Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.

When pregnancy is detected, discontinue telmisartan and amlodipine tablets as soon as possible [see Use in Specific Populations (8.1)].

5.2 Hypotension Telmisartan

5.2 Hypotension Telmisartan In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan and amlodipine tablets. Either correct this condition prior to administration of telmisartan and amlodipine tablets, or start treatment under close medical supervision with a reduced dose.

If hypotension does occur, place the patient in the supine position and, if necessary, give an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized. Amlodipine Symptomatic hypotension is possible, particularly in patients with severe aortic stenosis.

Because of the gradual onset of action, acute hypotension is unlikely.

5.3 Hyperkalemia Telmisartan

5.3 Hyperkalemia Telmisartan Hyperkalemia may occur in patients on ARBs, particularly in patients with advanced renal impairment, heart failure, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels. Consider periodic determinations of serum electrolytes to detect possible electrolyte imbalances, particularly in patients at risk.

5.4 Patients with Impaired Hepatic Function

5.4 Patients with Impaired Hepatic Function Telmisartan As the majority of telmisartan is eliminated by biliary excretion, patients with biliary obstructive disorders or hepatic insufficiency can be expected to have reduced clearance. Initiate telmisartan at low doses and titrate slowly in these patients [see Dosage and Administration (2.5), Use in Specific Populations (8.6), and Clinical Pharmacology (12.3)].

Amlodipine Amlodipine is extensively metabolized by the liver and the plasma elimination half-life (t 1/2) is 56 hours in patients with impaired hepatic function. Since patients with hepatic impairment have decreased clearance of amlodipine, start amlodipine or add amlodipine at 2.5 mg in patients with hepatic impairment.

The lowest dose of telmisartan and amlodipine tablet is 40/5 mg; therefore, initial therapy with telmisartan and amlodipine tablet is not recommended in hepatically impaired patients [see Use in Specific Populations (8.6)].

5.5 Renal Function Impairment

5.5 Renal Function Impairment Telmisartan As a consequence of inhibiting the renin-angiotensin-aldosterone system, anticipate changes in renal function in susceptible individuals. In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure or renal dysfunction), treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death.

Similar results may be anticipated in patients treated with telmisartan [see Clinical Pharmacology (12.3)]. In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen were observed. There has been no long-term use of telmisartan in patients with unilateral or bilateral renal artery stenosis, but anticipate an effect similar to that seen with ACE inhibitors.

5.6 Dual Blockade of the Renin-Angiotensin-Aldosterone System (RAS)

5.6 Dual Blockade of the Renin-Angiotensin-Aldosterone System (RAS) Telmisartan Dual blockade of the RAS with angiotensin-receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. The ONTARGET trial enrolled 25,620 patients ≥55 years old with atherosclerotic disease or diabetes with end-organ damage, randomized them to telmisartan only, ramipril only, or the combination, and followed them for a median of 56 months.

Patients receiving the combination of telmisartan and ramipril did not obtain any additional benefit compared to monotherapy, but experienced an increased incidence of renal dysfunction (e.g., acute renal failure) compared with groups receiving telmisartan alone or ramipril alone. In most patients no benefit has been associated with using two RAS inhibitors concomitantly.

In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on telmisartan and amlodipine tablets and other agents that affect the RAS. Do not co-administer aliskiren with telmisartan and amlodipine tablets in patients with diabetes. Avoid concomitant use of aliskiren with telmisartan and amlodipine tablets in patients with renal impairment (GFR <60 mL/min /1.73 m²).

5.7 Risk of Myocardial Infarction or Increased Angina

5.7 Risk of Myocardial Infarction or Increased Angina Amlodipine Worsening angina and acute myocardial infarction can develop after starting or increasing the dose of telmisartan and amlodipine tablets, particularly in patients with severe obstructive coronary artery disease.

5.8 Heart Failure

5.8 Heart Failure Amlodipine Closely monitor patients with heart failure. Amlodipine (5 to 10 mg per day) has been studied in a placebo-controlled trial of 1153 patients with NYHA Class III or IV heart failure on stable doses of ACE inhibitor, digoxin, and diuretics. Follow-up was at least 6 months, with a mean of about 14 months.

There was no overall adverse effect on survival or cardiac morbidity (as defined by life-threatening arrhythmia, acute myocardial infarction, or hospitalization for worsened heart failure). Amlodipine has been compared to placebo in four 8 to 12 week studies of patients with NYHA class II/III heart failure, involving a total of 697 patients.

In these studies, there was no evidence of worsening of heart failure based on measures of exercise tolerance, NYHA classification, symptoms, or LVEF. In the PRAISE-2 study, 1654 patients with NYHA class III (80%) or IV (20%) heart failure without evidence of underlying ischemic disease, on stable doses of ACE inhibitor (99%), digitalis (99%), and diuretics (99%) were randomized 1:1 to receive placebo or amlodipine and followed for a mean of 33 months.

While there was no statistically significant difference between amlodipine and placebo in the primary endpoint of all-cause mortality (95% confidence limits from 8% reduction to 29% increase on amlodipine), there were more reports of pulmonary edema in the patients on amlodipine.

Drug interactions

Drug interactions (US label) US FDA label

NSAIDS: Increased risk of renal impairment and loss of antihypertensive effect (7) If simvastatin is co-administered with amlodipine, do not exceed doses greater than 20 mg daily of simvastatin (7) Do not co-administer aliskiren with telmisartan and amlodipine tablets in patients with diabetes (7.2)

7.1 Drug Interactions with Telmisartan and Amlodipine Tablets

7.1 Drug Interactions with Telmisartan and Amlodipine Tablets The pharmacokinetics of amlodipine and telmisartan are not altered when the drugs are co-administered. No drug interaction studies have been conducted with telmisartan and amlodipine tablets and other drugs, although studies have been conducted with the individual amlodipine and telmisartan components of telmisartan and amlodipine tablets, as described below:

7.2 Drug Interactions with Telmisartan Aliskiren

7.2 Drug Interactions with Telmisartan Aliskiren: Do not co-administer aliskiren with telmisartan and amlodipine tablets in patients with diabetes. Avoid use of aliskiren with telmisartan and amlodipine tablets in patients with renal impairment (GFR <60 mL/min). Digoxin: When telmisartan was co-administered with digoxin, median increases in digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed.

Therefore, monitor digoxin levels when initiating, adjusting, and discontinuing telmisartan for the purpose of keeping the digoxin level within the therapeutic range. Lithium: Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists including telmisartan.

Therefore, monitor serum lithium levels during concomitant use. Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including telmisartan, may result in deterioration of renal function, including possible acute renal failure.

These effects are usually reversible. Monitor renal function periodically in patients receiving telmisartan and NSAID therapy. The antihypertensive effect of angiotensin II receptor antagonists, including telmisartan may be attenuated by NSAIDs including selective COX-2 inhibitors.

7.3 Drug Interactions with Amlodipine

7.3 Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. Simvastatin: Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone.

Limit the dose of simvastatin in patients on amlodipine to 20 mg daily. Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. Frequent monitoring of trough blood levels of cyclosporin and tacrolimus and dose adjustment when appropriate is recommended. The following have no clinically relevant effects on the pharmacokinetics of amlodipine: cimetidine, grapefruit juice, magnesium and aluminum hydroxide antacid, sildenafil.

Amlodipine has no clinically relevant effects on the pharmacokinetics or pharmacodynamics of the following: atorvastatin, digoxin, warfarin. CYP3A4 Inhibitors: Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure.

Erythromycin co-administration in healthy volunteers did not significantly change amlodipine systemic exposure. However, strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, ritonavir) may increase the plasma concentrations of amlodipine to a greater extent. Monitor for symptoms of hypotension and edema when amlodipine is co-administered with CYP3A4 inhibitors.

CYP3A4 Inducers: No information is available on the quantitative effects of CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone, rifampicin, St. John’s Wort) on amlodipine. Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Telmisartan is not metabolized by the cytochrome P450 system and had no effects in vitro on cytochrome P450 enzymes, except for some inhibition of CYP2C19.

Telmisartan is not expected to interact with drugs that inhibit cytochrome P450 enzymes; it is also not expected to interact with drugs metabolized by cytochrome P450 enzymes, except for possible inhibition of the metabolism of drugs metabolized by CYP2C19.

CYP3A4 Inhibitors: Co-administration of a 180 mg daily dose of diltiazem with 5 mg amlodipine in elderly hypertensive patients resulted in a 60% increase in amlodipine systemic exposure.

However, strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, ritonavir) may increase the plasma concentrations of amlodipine to a greater extent.

Monitor for symptoms of hypotension and edema when amlodipine is co-administered with CYP3A4 inhibitors.

CYP3A4 Inducers: No information is available on the quantitative effects of CYP3A4 inducers ( e.g., carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone, rifampicin, St.

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers.

Adverse reactions

Adverse reactions (US label) US FDA label
  • In the placebo-controlled factorial design study, the most common reasons for discontinuation of therapy with telmisartan and amlodipine tablets were peripheral edema, dizziness, and hypotension, each leading to discontinuation of ≤0.5% of telmisartan and amlodipine tablets-treated patients. Adverse reactions that occurred at a ≥2% higher incidence on telmisartan and amlodipine tablets than placebo were peripheral edema (4.8% vs 0%), dizziness (3% vs 2.2%), and back pain (2.2% vs 0%). (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reactions rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Telmisartan and amlodipine tablets The concomitant use of telmisartan and amlodipine has been evaluated for safety in more than 3700 patients with hypertension; approximately 1900 of these patients were exposed for at least 6 months and over 160 of these patients were exposed for at least one year.

Adverse reactions have generally been mild and transient in nature and have only infrequently required discontinuation of therapy. In the placebo-controlled factorial design study, the population treated with a telmisartan and amlodipine combination had a mean age of 53 years and included approximately 50% males, 79% were Caucasian, 17% Blacks, and 4% Asians.

Patients received doses ranging from 20/2.5 mg to 80/10 mg orally, once daily. The frequency of adverse reactions was not related to gender, age, or race. The adverse reactions that occurred in the placebo-controlled factorial design trial in ≥2% of patients treated with telmisartan and amlodipine tablets and at a higher incidence in telmisartan and amlodipine tablets-treated patients (n=789) than placebo-treated patients (n=46) were peripheral edema (4.8% vs 0%), dizziness (3% vs 2.2%), and back pain (2.2% vs 0%).

Edema (other than peripheral edema), hypotension, and syncope were reported in <2% of patients treated with telmisartan and amlodipine tablets. In the placebo-controlled factorial design trial, discontinuation due to adverse events occurred in 2.2% of all treatment cells of patients in the telmisartan/amlodipine-treated patients and in 4.3% in the placebo-treated group.

The most common reasons for discontinuation of therapy with telmisartan and amlodipine tablets were peripheral edema, dizziness, and hypotension (each ≤0.5%). Peripheral edema is a known, dose-dependent adverse reaction of amlodipine, but not of telmisartan. In the factorial design study, the incidence of peripheral edema during the 8 week, randomized, double-blind treatment period was highest with amlodipine 10 mg monotherapy.

The incidence was notably lower when telmisartan was used in combination with amlodipine 10 mg. Table 1: Incidence of Peripheral Edema During the 8 Week Treatment Period Telmisartan Placebo 40 mg 80 mg Amlodipine Placebo 0% 0.8% 0.7% 5 mg 0.7% 1.4% 2.1% 10 mg 17.8% 6.2% 11.3% Telmisartan Telmisartan has been evaluated for safety in more than 3700 patients, including 1900 treated for over 6 months and more than 1300 for over one year.

Adverse experiences have generally been mild and transient in nature and have only infrequently required discontinuation of therapy. In placebo-controlled trials involving 1041 patients treated with various doses of telmisartan (20 to 160 mg) monotherapy for up to 12 weeks, an overall incidence of adverse events was similar to the patients treated with placebo.

Adverse events occurring at an incidence of ≥1% in patients treated with telmisartan and at a greater rate than in patients treated with placebo, irrespective of their causal association, are presented in Table 2. Table 2: Adverse Events Occurring at an Incidence of ≥1% in Patients Treated with Telmisartan and at a Greater Rate than Patients Treated with Placebo Telmisartan n=1455 % Placebo n=380 % Upper respiratory tract infection 7 6 Back pain 3 1 Sinusitis 3 2 Diarrhea 3 2 Pharyngitis 1 0 In addition to the adverse events in the table, the following events occurred at a rate of ≥1% but were at least as frequent in the placebo group: influenza-like symptoms, dyspepsia, myalgia, urinary tract infection, abdominal pain, headache, dizziness, pain, fatigue, coughing, hypertension, chest pain, nausea, and peripheral edema.

Discontinuation of therapy because of adverse events was required in 2.8% of 1455 patients treated with telmisartan tablets and 6.1% of 380 placebo patients in placebo-controlled clinical trials. The incidence of adverse events was not dose-related and did not correlate with gender, age, or race of patients. The incidence of cough occurring with telmisartan in 6 placebo-controlled trials was identical to that noted for placebo-treated patients (1.6%).

In addition to those listed above, adverse events that occurred in >0.3% of 3500 patients treated with telmisartan monotherapy in controlled or open trials are listed below. It cannot be determined whether these events were causally related to telmisartan tablets: Autonomic Nervous System: impotence, increased sweating, flushing; Body as a Whole: allergy, fever, leg pain, malaise; Cardiovascular: palpitation, dependent edema, angina pectoris, tachycardia, leg edema, abnormal ECG; CNS: insomnia, somnolence, migraine, vertigo, paresthesia, involuntary muscle contractions, hypoesthesia; Gastrointestinal: flatulence, constipation, gastritis, vomiting, dry mouth, hemorrhoids, gastroenteritis, enteritis, gastroesophageal reflux, toothache, nonspecific gastrointestinal disorders; Metabolic: gout, hypercholesterolemia, diabetes mellitus; Musculoskeletal: arthritis, arthralgia, leg cramps; Psychiatric: anxiety, depression, nervousness; Resistance Mechanism: infection, fungal infection, abscess, otitis media; Respiratory: asthma, bronchitis, rhinitis, dyspnea, epistaxis; Skin: dermatitis, rash, eczema, pruritus; Urinary: micturition frequency, cystitis; Vascular: cerebrovascular disorder; and Special Senses: abnormal vision, conjunctivitis, tinnitus, earache.

During initial clinical studies, a single case of angioedema was reported (among a total of 3781 patients treated). Clinical Laboratory Findings In placebo-controlled clinical trials, clinically relevant changes in standard laboratory test parameters were rarely associated with administration of telmisartan tablets. Hemoglobin: A greater than 2 g/dL decrease in hemoglobin was observed in 0.8% telmisartan patients compared with 0.3% placebo patients.

No patients discontinued therapy due to anemia. Creatinine: A 0.5 mg/dL rise or greater in creatinine was observed in 0.4% telmisartan patients compared with 0.3% placebo patients. One telmisartan-treated patient discontinued therapy due to increases in creatinine and blood urea nitrogen. Liver Enzymes: Occasional elevations of liver chemistries occurred in patients treated with telmisartan; all marked elevations occurred at a higher frequency with placebo.

No telmisartan-treated patients discontinued therapy due to abnormal hepatic function. Amlodipine Amlodipine has been evaluated for safety in more than 11,000 patients in U.S. and foreign clinical trials. Most adverse reactions reported during therapy with amlodipine were of mild or moderate severity. In controlled clinical trials directly comparing amlodipine (n=1730) in doses up to 10 mg to placebo (n=1250), discontinuation of amlodipine due to adverse reactions was required in only about 1.5% of amlodipine-treated patients and was not significantly different from that seen in placebo-treated patients (about 1%).

The most common side effects were headache and edema. The incidence (%) of side effects which occurred in a dose-related manner are presented in Table 3. Table 3: Incidence (%) of Dose-Related Adverse Effects with Amlodipine at Doses of 2.5 mg, 5 mg, and 10 mg or Placebo Adverse Event Amlodipine 2.5 mg n=275 % Amlodipine 5 mg n=296 % Amlodipine 10 mg n=268 % Placebo n=520 % Edema 1.8 3 10.8 0.6 Dizziness 1.1 3.4 3.4 1.5 Flushing 0.7 1.4 2.6 0 Palpitations 0.7 1.4 4.5 0.6 Other adverse experiences which were not clearly dose related but which were reported with an incidence greater than 1% in placebo-controlled clinical trials are presented in Table 4.

Table 4: Incidence (%) of Adverse Effects Not Clearly Dose Related but Reported at an Incidence of >1% in Placebo-Controlled Clinical Trials Adverse Event Amlodipine n=1730 % Placebo n=1250 % Headache 7.3 7.8 Fatigue 4.5 2.8 Nausea 2.9 1.9 Abdominal pain 1.6 0.3 Somnolence 1.4 0.6 The following events occurred in <1% but >0.1% of patients in controlled clinical trials or under conditions of open trials or marketing experience where a causal relationship is uncertain; they are listed to alert the physician to a possible relationship: Cardiovascular: arrhythmia (including ventricular tachycardia and atrial fibrillation), bradycardia, chest pain, hypotension, peripheral ischemia, syncope, tachycardia, postural dizziness, postural hypotension, vasculitis; Central and Peripheral Nervous System: hypoesthesia, neuropathy peripheral, paresthesia, tremor, vertigo; Gastrointestinal: anorexia, constipation, dyspepsia,** dysphagia, diarrhea, flatulence, pancreatitis, vomiting, gingival hyperplasia, change of bowel habit; General: allergic reaction, asthenia,** back pain, hot flushes, malaise, pain, rigors, weight gain, weight decrease; Musculoskeletal System: arthralgia, arthrosis, muscle cramps,** myalgia; Psychiatric: sexual dysfunction (male** and female), insomnia, nervousness, depression, abnormal dreams, anxiety, depersonalization, mood change; Respiratory System: dyspnea,** epistaxis; Skin and Appendages: angioedema, erythema multiforme, pruritus,** rash,** rash erythematous, rash maculopapular; Special Senses: abnormal vision, conjunctivitis, diplopia, eye pain, tinnitus; Urinary System: micturition frequency, micturition disorder, nocturia; Autonomic Nervous System: dry mouth, sweating increased; Metabolic and Nutritional: hyperglycemia, thirst; Hemopoietic: leukopenia, purpura, thrombocytopenia. **These events occurred in less than 1% in placebo-controlled trials, but the incidence of these side effects was between 1% and 2% in all multiple dose studies. The following events occurred in <0.1% of patients: cardiac failure, pulse irregularity, extrasystoles, skin discoloration, urticaria, skin dryness, alopecia, dermatitis, muscle weakness, twitching, ataxia, hypertonia, migraine, cold and clammy skin, apathy, agitation, amnesia, gastritis, increased appetite, loose stools, coughing, rhinitis, dysuria, polyuria, parosmia, taste perversion, abnormal visual accommodation, and xerophthalmia.

Other reactions occurred sporadically and cannot be distinguished from medications or concurrent disease states such as myocardial infarction and angina. Amlodipine has not been associated with clinically significant changes in routine laboratory tests. No clinically relevant changes were noted in serum potassium, serum glucose, total triglycerides, total cholesterol, HDL cholesterol, uric acid, blood urea nitrogen, or creatinine.

Amlodipine has been used safely in patients with chronic obstructive pulmonary disease, well-compensated congestive heart failure, coronary artery disease, peripheral vascular disease, diabetes mellitus, and abnormal lipid profiles. Adverse reactions reported for amlodipine for indications other than hypertension may be found in the prescribing information for Norvasc ®.

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of telmisartan or amlodipine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure.

Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to telmisartan or amlodipine. Telmisartan The most frequently spontaneously reported events include: headache, dizziness, asthenia, coughing, nausea, fatigue, weakness, edema, face edema, lower limb edema, angioneurotic edema, urticaria, hypersensitivity, sweating increased, erythema, chest pain, atrial fibrillation, congestive heart failure, myocardial infarction, blood pressure increased, hypertension aggravated, hypotension (including postural hypotension), hyperkalemia, syncope, dyspepsia, diarrhea, pain, urinary tract infection, erectile dysfunction, back pain, abdominal pain, muscle cramps (including leg cramps), myalgia, bradycardia, eosinophilia, thrombocytopenia, uric acid increased, abnormal hepatic function/liver disorder, renal impairment including acute renal failure, anemia, and increased CPK, anaphylactic reaction, tendon pain (including tendonitis, tenosynovitis), drug eruption (e.g. toxic skin eruption mostly reported as toxicoderma, rash, and urticaria), hypoglycemia (in diabetic patients), and angioedema (with fatal outcome).

Rare cases of rhabdomyolysis have been reported in patients receiving angiotensin II receptor blockers, including telmisartan. Amlodipine Gynecomastia has been reported infrequently and a causal relationship is uncertain. Jaundice and hepatic enzyme elevations (mostly consistent with cholestasis or hepatitis), in some cases severe enough to require hospitalization, have been reported in association with use of amlodipine.

Postmarketing reporting has also revealed a possible association between extrapyramidal disorder and amlodipine.

Adverse reaction frequency tables (US label) US FDA label
Telmisartan
Placebo 40 mg 80 mg
Amlodipine Placebo 0% 0.8% 0.7%
5 mg 0.7% 1.4% 2.1%
10 mg 17.8% 6.2% 11.3%
Telmisartan n=1455 % Placebo n=380 %
Upper respiratory tract infection 7 6
Back pain 3 1
Sinusitis 3 2
Diarrhea 3 2
Pharyngitis 1 0
Adverse Event Amlodipine 2.5 mg n=275 % Amlodipine 5 mg n=296 % Amlodipine 10 mg n=268 % Placebo n=520 %
Edema 1.8 3 10.8 0.6
Dizziness 1.1 3.4 3.4 1.5
Flushing 0.7 1.4 2.6 0
Palpitations 0.7 1.4 4.5 0.6
Adverse Event Amlodipine n=1730 % Placebo n=1250 %
Headache 7.3 7.8
Fatigue 4.5 2.8
Nausea 2.9 1.9
Abdominal pain 1.6 0.3
Somnolence 1.4 0.6

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Telmisartan and amlodipine tablets can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death (see clinical consideration).

Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Studies in rats and rabbits with telmisartan showed fetotoxicity only at maternally toxic doses (see Data).

In animal reproduction studies, there was no evidence of adverse developmental effects when pregnant rats and rabbits were treated orally with amlodipine maleate during organogenesis at doses approximately 10 and 20-times the maximum recommended human dose (MRHD), respectively. However for rats, litter size was significantly decreased (by about 50%) and the number of intrauterine deaths was significantly increased (about 5-fold).

Amlodipine has been shown to prolong both the gestation period and the duration of labor in rats at this dose (see Data). When pregnancy is detected, discontinue telmisartan and amlodipine tablets as soon as possible. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major malformations and miscarriage in clinically recognized pregnancies is 2% to 4%, and 15% to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage).

Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. Pregnant women with hypertension should be carefully monitored and managed accordingly. Fetal/Neonatal adverse reactions Use of drugs that act on the RAS in the second and third trimesters of pregnancy can result in the following: oligohydramnios, reduced fetal renal function leading to anuria and renal failure, fetal lung hypoplasia, skeletal deformations, including skull hypoplasia, hypotension, and death.

In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. In patients taking telmisartan and amlodipine tablets during pregnancy, perform serial ultrasound examinations to assess the intra-amniotic environment.

Fetal testing may be appropriate, based on the week of gestation. If oligohydramnios is observed, discontinue telmisartan and amlodipine tablets, unless it is considered lifesaving for the mother. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury.

Closely observe infants with histories of in utero exposure to telmisartan and amlodipine tablets for hypotension, oliguria, and hyperkalemia. If oliguria or hypotension occurs, support blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function [see Use in Specific Populations (8.4)].

Data Animal Data No reproductive toxicity studies have been conducted with the combination of telmisartan and amlodipine besylate. However, these studies have been conducted for telmisartan and amlodipine besylate alone. Telmisartan No teratogenic effects were observed when telmisartan was administered to pregnant rats at oral doses of up to 50 mg/kg/day and to pregnant rabbits at oral doses up to 45 mg/kg/day.

In rabbits, embryolethality associated with maternal toxicity (reduced body weight gain and food consumption) was observed at 45 mg/kg/day [about 12 times the maximum recommended human dose (MRHD) of 80 mg on a mg/m 2 basis]. In rats, maternally toxic (reduction in body weight gain and food consumption) telmisartan doses of 15 mg/kg/day (about 1.9 times the MRHD on a mg/m 2 basis), administered during late gestation and lactation, were observed to produce adverse effects in neonates, including reduced viability, low birth weight, delayed maturation, and decreased weight gain.

The no observed effect doses for developmental toxicity in rats and rabbits, 5 and 15 mg/kg/day, respectively, are about 0.64 and 3.7 times, on a mg/m 2 basis, the maximum recommended human dose of telmisartan (80 mg/day). Amlodipine No evidence of teratogenicity or embryo/fetal toxicity was found when pregnant rats and rabbits were treated orally with amlodipine maleate at doses up to 10 mg amlodipine/kg/day (approximately 10 and 20 times the MRHD based on body surface area, respectively) during their respective periods of major organogenesis.

However, for rats, litter size was significantly decreased (by about 50%) and the number of intrauterine deaths was significantly increased (about 5-fold). Amlodipine has been shown to prolong both the gestation period and the duration of labor in rats at this dose.

Mechanism of action

12.1 Mechanism of Action Telmisartan Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium.

Telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin II synthesis. There is also an AT 2 receptor found in many tissues, but AT 2 is not known to be associated with cardiovascular homeostasis.

Telmisartan has much greater affinity (>3,000 fold) for the AT 1 receptor than for the AT 2 receptor. Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is widely used in the treatment of hypertension. ACE inhibitors also inhibit the degradation of bradykinin, a reaction also catalyzed by ACE.

Because telmisartan does not inhibit ACE (kininase II), it does not affect the response to bradykinin. Whether this difference has clinical relevance is not yet known. Telmisartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation. Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of telmisartan on blood pressure.

Amlodipine Amlodipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels.

Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Negative inotropic effects can be detected in vitro but such effects have not been seen in intact animals at therapeutic doses. Serum calcium concentration is not affected by amlodipine.

Within the physiologic pH range, amlodipine is an ionized compound (pKa=8.6), and its kinetic interaction with the calcium channel receptor is characterized by a gradual rate of association and dissociation with the receptor binding site, resulting in a gradual onset of effect. Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Telmisartan and Amlodipine Tablets Telmisartan and amlodipine tablets have been shown to be effective in lowering blood pressure. Telmisartan and amlodipine tablets are a combination of two drugs with antihypertensive properties: a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker), amlodipine besylate, and an angiotensin II receptor blocker, telmisartan.

Both telmisartan and amlodipine, lower blood pressure by reducing peripheral resistance but through complementary mechanisms. Telmisartan In normal volunteers, a dose of telmisartan 80 mg inhibited the pressor response to an intravenous infusion of angiotensin II by about 90% at peak plasma concentrations with approximately 40% inhibition persisting for 24 hours.

Plasma concentration of angiotensin II and plasma renin activity (PRA) increased in a dose-dependent manner after single administration of telmisartan to healthy subjects and repeated administration to hypertensive patients. The once-daily administration of up to 80 mg telmisartan to healthy subjects did not influence plasma aldosterone concentrations.

In multiple dose studies with hypertensive patients, there were no clinically significant changes in electrolytes (serum potassium or sodium), or in metabolic function (including serum levels of cholesterol, triglycerides, HDL, LDL, glucose, or uric acid). In 30 hypertensive patients with normal renal function treated for 8 weeks with telmisartan 80 mg or telmisartan 80 mg in combination with hydrochlorothiazide 12.5 mg, there were no clinically significant changes from baseline in renal blood flow, glomerular filtration rate, filtration fraction, renovascular resistance, or creatinine clearance.

Telmisartan has indications other than hypertension which can be found in the Micardis® (telmisartan) tablets package insert. Amlodipine Following administration of therapeutic doses to patients with hypertension, amlodipine produces vasodilation resulting in a reduction of supine and standing blood pressures. These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chronic dosing.

Although the acute intravenous administration of amlodipine decreases arterial blood pressure and increases heart rate in hemodynamic studies of patients with chronic stable angina, chronic oral administration of amlodipine in clinical trials did not lead to clinically significant changes in heart rate or blood pressures in normotensive patients with angina. With chronic once daily administration, antihypertensive effectiveness is maintained for at least 24 hours.

Plasma concentrations correlate with effect in both young and elderly patients. The magnitude of reduction in blood pressure with amlodipine is also correlated with the height of pretreatment elevation; thus, individuals with moderate hypertension (diastolic pressure 105 to 114 mmHg) had about a 50% greater response than patients with mild hypertension (diastolic pressure 90 to 104 mmHg).

Normotensive subjects experienced no clinically significant change in blood pressure (+1/-2 mmHg). In hypertensive patients with normal renal function, therapeutic doses of amlodipine resulted in a decrease in renal vascular resistance and an increase in glomerular filtration rate and effective renal plasma flow without change in filtration fraction or proteinuria.

As with other calcium channel blockers, hemodynamic measurements of cardiac function at rest and during exercise (or pacing) in patients with normal ventricular function treated with amlodipine have generally demonstrated a small increase in cardiac index without significant influence on dP/dt or on left ventricular end diastolic pressure or volume. In hemodynamic studies, amlodipine has not been associated with a negative inotropic effect when administered in the therapeutic dose range to intact animals and man, even when co-administered with beta-blockers to man.

Similar findings, however, have been observed in normal or well-compensated patients with heart failure with agents possessing significant negative inotropic effects. Amlodipine does not change sinoatrial nodal function or atrioventricular conduction in intact animals or man. In patients with chronic stable angina, intravenous administration of 10 mg did not significantly alter A-H and H-V conduction and sinus node recovery time after pacing.

Similar results were obtained in patients receiving amlodipine and concomitant beta-blockers. In clinical studies in which amlodipine was administered in combination with beta-blockers to patients with either hypertension or angina, no adverse effects of electrocardiographic parameters were observed. In clinical trials with angina patients alone, amlodipine therapy did not alter electrocardiographic intervals or produce higher degrees of AV blocks.

Amlodipine has indications other than hypertension which can be found in the Norvasc® package insert.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Telmisartan shows bi-exponential decay kinetics with a terminal elimination half life of approximately 24 hours.

Elimination of amlodipine from the plasma is biphasic with a terminal elimination half-life of about 30 to 50 hours.

Metabolism and Elimination Telmisartan Following either intravenous or oral administration of 14 C-labeled telmisartan, most of the administered dose (>97%) was eliminated unchanged in feces via biliary excretion; only minute amounts were found in the urine (0.91% and 0.49% of total radioactivity, respectively).

Terminal half-life and total clearance appear to be independent of dose.

Amlodipine Amlodipine is extensively (about 90%) converted to inactive metabolites via hepatic metabolism with 10% of the parent compound and 60% of the metabolites excreted in the urine.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Telmisartan and Amlodipine Tablets The pharmacokinetics of amlodipine and telmisartan when combined are similar to the pharmacokinetics of amlodipine and telmisartan when administered separately. After administering telmisartan and amlodipine 80/10 mg tablet with a high-fat meal, the total area under the plasma concentration-time curve (AUC) and C max for telmisartan decreased by about 24% and 60%, respectively.

For amlodipine, AUC and C max were not altered [see Dosage and Administration (2.1)]. Telmisartan Following oral administration, peak concentrations (C max) of telmisartan are reached in 0.5 to 1 hour after dosing. Food slightly reduces the bioavailability of telmisartan, with a reduction in the area under the plasma concentration-time curve (AUC) of about 6% with the 40 mg tablet and about 20% after a 160 mg dose.

The absolute bioavailability of telmisartan is dose dependent. At 40 and 160 mg the bioavailability was 42% and 58%, respectively. The pharmacokinetics of orally administered telmisartan are nonlinear over the dose range 20 to 160 mg, with greater than proportional increases of plasma concentrations (C max and AUC) with increasing doses.

Telmisartan shows bi-exponential decay kinetics with a terminal elimination half life of approximately 24 hours. Trough plasma concentrations of telmisartan with once daily dosing are about 10% to 25% of peak plasma concentrations. Telmisartan has an accumulation index in plasma of 1.5 to 2 upon repeated once daily dosing.

Amlodipine Peak plasma concentrations of amlodipine are reached 6 to 12 hours after administration of amlodipine alone. Absolute bioavailability has been estimated to be between 64% and 90%. The bioavailability of amlodipine is not altered by the presence of food. Elimination of amlodipine from the plasma is biphasic with a terminal elimination half-life of about 30 to 50 hours.

Steady state plasma levels of amlodipine are reached after 7 to 8 days of consecutive daily dosing. Distribution Telmisartan Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 -acid glycoprotein. Plasma protein binding is constant over the concentration range achieved with recommended doses. The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.

Amlodipine The apparent volume of distribution of amlodipine is 21 L/kg. Approximately 93% of circulating amlodipine is bound to plasma proteins in hypertensive patients. Metabolism and Elimination Telmisartan Following either intravenous or oral administration of 14 C-labeled telmisartan, most of the administered dose (>97%) was eliminated unchanged in feces via biliary excretion; only minute amounts were found in the urine (0.91% and 0.49% of total radioactivity, respectively).

Telmisartan is metabolized by conjugation to form a pharmacologically inactive acylglucuronide; the glucuronide of the parent compound is the only metabolite that has been identified in human plasma and urine. After a single dose, the glucuronide represents approximately 11% of the measured radioactivity in plasma. The cytochrome P450 isoenzymes are not involved in the metabolism of telmisartan.

Total plasma clearance of telmisartan is >800 mL/min. Terminal half-life and total clearance appear to be independent of dose. Amlodipine Amlodipine is extensively (about 90%) converted to inactive metabolites via hepatic metabolism with 10% of the parent compound and 60% of the metabolites excreted in the urine. Specific Populations Renal Insufficiency Telmisartan: No dosage adjustment is necessary in patients with decreased renal function.

Telmisartan is not removed from blood by hemofiltration [see Warnings and Precautions (5.5)]. Amlodipine: The pharmacokinetics of amlodipine are not significantly influenced by renal impairment. Patients with renal failure may therefore receive the usual initial dose. Hepatic Insufficiency Telmisartan: In patients with hepatic insufficiency, plasma concentrations of telmisartan are increased, and absolute bioavailability approaches 100% [see Warnings and Precautions (5.4) and Use in Specific Populations (8.6)].

Amlodipine: Patients with hepatic insufficiency have decreased clearance of amlodipine with a resulting increase in AUC of approximately 40% to 60%. Therefore, start with a low initial dose of amlodipine. Gender Plasma concentrations of telmisartan are generally 2 to 3 times higher in females than in males. In clinical trials, however, no significant increases in blood pressure response or in the incidence of orthostatic hypotension were found in women.

No dosage adjustment is necessary. Geriatric Patients Telmisartan: The pharmacokinetics of telmisartan do not differ between the elderly and those younger than 65 years [see Dosage and Administration (2.1)]. Amlodipine: Elderly patients have decreased clearance of amlodipine with a resulting increase in AUC of approximately 40% to 60%.

Therefore, start with a low initial dose of amlodipine [see Dosage and Administration (2.5)]. Drug Interaction Studies Telmisartan Ramipril and Ramiprilat: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state C max and AUC of ramipril 2.3- and 2.1-fold, respectively, and C max and AUC of ramiprilat 2.4- and 1.5-fold, respectively.

In contrast, C max and AUC of telmisartan decrease by 31% and 16%, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.

Other Drugs: Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glyburide, simvastatin, hydrochlorothiazide, warfarin, or ibuprofen. Telmisartan is not metabolized by the cytochrome P450 system and had no effects in vitro on cytochrome P450 enzymes, except for some inhibition of CYP2C19.

Telmisartan is not expected to interact with drugs that inhibit cytochrome P450 enzymes; it is also not expected to interact with drugs metabolized by cytochrome P450 enzymes, except for possible inhibition of the metabolism of drugs metabolized by CYP2C19.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Telmisartan and Amlodipine · Alembic Pharmaceuticals Limited [US FDA-approved label, version 5, October 26, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15b438b4-4874-43f4-a50a-4e6f3e5530ac
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .